TGTX catalyst calendar

TG THERAPEUTICS, INC.

Upcoming catalysts
9
Cash runway
92.6 months
Cash & investments
$552M
Phase 3 programs
10

TG THERAPEUTICS, INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS) on October 31, 2026. There are 9 upcoming events on record.

Cash runway is approximately 92.6 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 28 concluded trials, 54% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
October 31, 2026 A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS) Trial Milestone Phase 3
November 2, 2026 est. Next quarterly earnings (projected) Earnings —
December 1, 2026 A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders Trial Milestone Phase 1
January 21, 2027 Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab Trial Milestone Phase 3
July 31, 2027 A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS) Trial Milestone Phase 2
July 1, 2028 A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG) Trial Milestone Phase 2
December 12, 2028 Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia Trial Milestone Phase 2
January 1, 2030 Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis Trial Milestone Phase 2/Phase 3
May 31, 2032 An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis Trial Milestone Phase 3

Track TGTX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open TGTX in the tracker

Recent history

DateEventTypePhase
August 3, 2026 Quarterly results filed (8-K) Earnings —
June 3, 2026 8-K filed: Other event Filing —
May 27, 2026 8-K filed: Other event Filing —
May 6, 2026 Quarterly results filed (8-K) Earnings —
March 20, 2026 8-K filed: Material agreement Corporate —
February 26, 2026 Quarterly results filed (8-K) Earnings —
January 13, 2026 8-K filed: Reg FD disclosure Filing —
November 3, 2025 Quarterly results filed (8-K) Earnings —
August 4, 2025 Quarterly results filed (8-K) Earnings —
May 5, 2025 Quarterly results filed (8-K) Earnings —
June 12, 2024 Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia Trial Milestone Phase 1
May 21, 2024 Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies Trial Milestone Phase 1
February 21, 2024 Study of TG-1801 in Subjects With B-Cell Lymphoma Trial Milestone Phase 1
February 22, 2023 Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia Trial Milestone Phase 3
December 20, 2022 Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) Trial Milestone Phase 2/Phase 3
November 11, 2022 An Extension of the TG1101-RMS201 Trial Trial Milestone Phase 2
May 31, 2022 Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma Trial Milestone Phase 2/Phase 3
May 26, 2022 A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304 Trial Milestone Phase 2
May 26, 2022 Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL Trial Milestone Phase 1/Phase 2
May 25, 2022 Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials Trial Milestone Phase 2
May 22, 2022 Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax Trial Milestone Phase 2
May 16, 2022 Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma Trial Milestone Phase 2
May 3, 2022 Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma Trial Milestone Phase 1
February 15, 2022 Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma Trial Milestone Phase 2
November 4, 2021 Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation Trial Milestone Phase 1
June 10, 2021 Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy Trial Milestone Phase 2
August 4, 2020 Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) Trial Milestone Phase 3
July 23, 2020 Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 ) Trial Milestone Phase 3
April 1, 2020 Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) Trial Milestone Phase 3
October 15, 2019 Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies Trial Milestone Phase 1

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.